These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25792842)

  • 41. Corrigendum.
    Sun XH; Yu HZ; Yang MM; Yang YM; Dang ZM
    J Cachexia Sarcopenia Muscle; 2015 Jun; 6(2):192. PubMed ID: 26140254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review.
    Ishihara A; Hatakeyama S; Suzuki J; Amano Y; Sasahara T; Toshima M; Morisawa Y
    BMC Infect Dis; 2019 Oct; 19(1):848. PubMed ID: 31615436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erratum: MTBP promotes migration and invasion by regulation of ZEB2-mediated epithelial-mesenchymal transition in lung cancer cells [Corrigendum].
    Onco Targets Ther; 2018; 11():8357. PubMed ID: 30568458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erratum: Drug prescription appropriateness in the elderly: an Italian study [Corrigendum].
    Clin Interv Aging; 2017; 12():2131. PubMed ID: 29290683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx
    Robella M; Vaira M; Argenziano M; Spagnolo R; Cavalli R; Borsano A; Gentilli S; De Simone M
    Front Pharmacol; 2019; 10():669. PubMed ID: 31293417
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
    Lorusso D; Sabatucci I; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
    Tumori; 2019 Aug; 105(4):282-287. PubMed ID: 30917765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
    Fedders M; Hartmann M; Schneider A; Kath R; Camara O; Oelschläger H
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):619-25. PubMed ID: 17458562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
    Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
    J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erratum: Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient population [Corrigendum].
    Clin Ophthalmol; 2016; 10():2475. PubMed ID: 28003736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
    Colombo N; Hardy-Bessard AC; Ferrandina G; Marth C; Romero I
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):11-19. PubMed ID: 27797622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
    English JC; Toney R; Patterson JW
    J Cutan Pathol; 2003 Oct; 30(9):591-5. PubMed ID: 14507411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erratum: Diversity and evolution of drug resistance mechanisms in
    Infect Drug Resist; 2018; 11():1. PubMed ID: 29319057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
    Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Giovinazzo H; Kumar P; Sheikh A; Brooks KM; Ivanovic M; Walsh M; Caron WP; Kowalsky RJ; Song G; Whitlow A; Clarke-Pearson DL; Brewster WR; Van Le L; Zamboni BA; Bae-Jump V; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):565-73. PubMed ID: 26822231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erratum: Synthesis of biocompatible iron oxide nanoparticles as a drug delivery vehicle [Corrigendum].
    Int J Nanomedicine; 2018; 13():4207-4208. PubMed ID: 30050298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erratum: Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum].
    Infect Drug Resist; 2016; 9():43-5. PubMed ID: 27099523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erratum: Obstructive sleep apnea affects the clinical outcomes of patients undergoing percutaneous coronary intervention [Corrigendum].
    Patient Prefer Adherence; 2016; 10():1159. PubMed ID: 27418811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.